Evidence map›Paper›PMID 39734600›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2024

Late-Onset Ocular Hypotensive Effect of Ripasudil on Primary Open-Angle Glaucoma.

Kei Sano, Ryo Terauchi, Kota Fukai, Shumpei Ogawa, Takahiko Noro, Masayuki Tatemichi, Tadashi Nakano

Abstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kei SanoDepartment of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.
Ryo TerauchiDepartment of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.ORCID 0000-0002-6714-2543
Kota FukaiDepartment of Preventive Medicine, Tokai University School of Medicine, Isehara, 259-1193, Japan.
Shumpei OgawaDepartment of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.ORCID 0000-0003-3841-6004
Takahiko NoroDepartment of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.ORCID 0000-0001-9147-5455
Masayuki TatemichiDepartment of Preventive Medicine, Tokai University School of Medicine, Isehara, 259-1193, Japan.
Tadashi NakanoDepartment of Ophthalmology, The Jikei University School of Medicine, Tokyo, 105-8461, Japan.ORCID 0000-0002-3184-1991

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: We evaluated the late-onset ocular hypotensive effect of ripasudil after long-term administration in real-world clinical data and investigated its associated factors in primary open-angle glaucoma (POAG). Patients and Methods: We reviewed the clinical patients with POAG who newly started ripasudil without changes of treatment. Enrolled eyes were assigned to two groups: positive group with the late-onset effect and negative group. Eyes that show the late-onset effect 6 months after starting ripasudil were defined as positive. Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the late-onset effect. Results: We enrolled 74 eyes of 74 patients with POAG (age, 67.5 ± 10.9 years; mean deviation, -11.2 ± 5.9 dB) and followed them for 14.2 ± 5.0 months. Among them, 12 (16.2%) eyes were assigned to the positive group. Retinal nerve fiber layer (RNFL) thickness (73.4 ± 12.9 vs 64.0 ± 9.8 μm, Conclusion: Some patients with POAG showed the late-onset IOP-lowering effect of ripasudil, and its associated factors were higher IOP and thicker RNFL. The addition of ripasudil may offer potential benefits particularly for early-stage glaucoma with thicker RNFL.

Indexed as

glaucomaintraocular pressureocular hypertensionripasudilROCK-inhibitor

Identifiers

PMID39734600
PMCPMC11681902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.